NURIX THERAPEUTICS, INC. Contract Liability (Deferred Revenue)
NURIX THERAPEUTICS, INC. (NRIX) had Contract Liability (Deferred Revenue) of $13.32 million as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-09
- 2026-05-31: Contract with Customer, Liability, Current $13.32M.
- 2026-02-28: Contract with Customer, Liability, Current $18.75M.
- 2025-11-30: Contract with Customer, Liability, Current $17.58M.
- 2025-08-31: Contract with Customer, Liability, Current $25.99M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-05-31 | $13.32M 10-Q · filed 2026-07-09 |
| 2026-02-28 | $18.75M 10-Q · filed 2026-04-08 |
| 2025-11-30 | $17.58M 10-Q · filed 2026-07-09 |
| 2025-08-31 | $25.99M 10-Q · filed 2025-10-09 |
| 2025-05-31 | $27.42M 10-Q · filed 2025-07-09 |
| 2025-02-28 | $30.59M 10-Q · filed 2025-04-08 |
| 2024-11-30 | $38.36M 10-K · filed 2026-01-28 |
| 2024-08-31 | $48.00M 10-Q · filed 2024-10-11 |
| 2024-05-31 | $46.77M 10-Q · filed 2024-07-11 |
| 2024-02-29 | $46.08M 10-Q · filed 2024-04-10 |
| 2023-11-30 | $48.10M 10-K · filed 2025-01-28 |
| 2023-08-31 | $32.04M 10-Q · filed 2023-10-12 |
| 2023-05-31 | $44.06M 10-Q · filed 2023-07-13 |
| 2023-02-28 | $38.30M 10-Q · filed 2023-04-13 |
| 2022-11-30 | $37.63M 10-K · filed 2024-02-15 |
| 2022-08-31 | $36.34M 10-Q · filed 2022-10-06 |
| 2022-05-31 | $41.32M 10-Q · filed 2022-07-07 |
| 2022-02-28 | $43.19M 10-Q · filed 2022-04-08 |
| 2021-11-30 | $41.21M 10-K · filed 2023-02-09 |
| 2021-08-31 | $35.25M 10-Q · filed 2021-10-14 |
| 2021-05-31 | $33.76M 10-Q · filed 2021-07-13 |
| 2021-02-28 | $32.75M 10-Q · filed 2021-04-13 |
| 2020-11-30 | $32.80M 10-K · filed 2022-01-28 |
| 2020-08-31 | $30.30M 10-Q · filed 2020-10-14 |
| 2019-11-30 | $9.61M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |